Essayer OR - Gratuit
Singapore develops blood test to improve prediction of gestational diabetes
BioSpectrum Asia
|BioSpectrum Asia Sep 2025
Researchers from the Global Centre for Asian Women's Health (GloW) and the Department of Obstetrics and Gynecology at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have found that selected maternal biomarkers from first-trimester random blood samples can effectively predict a woman's risk of gestational diabetes mellitus (GDM).
-
In Singapore, GDM which affects one in five pregnant women-is typically diagnosed with a three-point oral glucose tolerance test between 24 and 28 weeks of pregnancy.
Cette histoire est tirée de l'édition BioSpectrum Asia Sep 2025 de BioSpectrum Asia.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE BioSpectrum Asia
BioSpectrum Asia
The Race to Build Singapore's Biotech Unicorns
MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"
As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leprosy Isn't Over: South-East Asia's Unfinished Fight
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
2 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Strategic Rise of India's Deep-Science Economy
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Japan strengthening biopharma capabilities
Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.
7 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Cancer Diagnosis, Accelerated by AI
Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.
13 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026
The oncology landscape in Asia stands at a critical juncture.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Pharma M&A set to boom in 2026
After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.
3 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 mins
BioSpectrum Asia Jan 2026
Listen
Translate
Change font size